Ownership history in ROYCE & ASSOCIATES LP Β· 28 quarters on record
This page tracks every 13F SEC filing in which ROYCE & ASSOCIATES LP reported a position in APYX MED CORP (APYX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π ROYCE & ASSOCIATES LP outperformed the S&P 500 by +2.3% annually on this APYX position. Timing score: 43% (10/23 decisions correct). Average cost basis: $3.43. Maximum drawdown during holding period: β91.0%.
β
Outperformed SPY on this position by 2.3% ann.
26 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
10 of 23 add/trim decisions correct
Best entry: $1.24 (2024 Q3) Β· Worst: $8.46 (2019 Q4)
πͺ Held through 2 major drawdowns (>20%).
15 adds Β· 10 trims. Bought during 9 of 14 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.09% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size